Pharmaxis   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: New Farm Australia (1998)

Organization Overview

First Clinical Trial
2004
NCT00455130
First Marketed Drug
2010
mannitol
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Pharmaxis | PHARMAXIS LTD | Pharmaxis Ltd Australia | Pharmaxis Ltd, Sydney, NSW, Australia

Active Ingredients

Marketed Drugs (1)

mannitol (2010)

Drugs in Phase 3 Trials (2)

mannitol (19 trials)

methacholine (provocholine) (2 trials)

Drugs in Phase 2 Trials (8)

albuterol (proventil) (2 trials)

asm8 (3 trials)

budesonide (rhinocort) (3 trials)

dornase alfa (pulmozyme) (1 trial)

ipratropium (atrovent) (1 trial)

pxs-5505 (1 trial)

tpi1020 (2 trials)

tpi asm8 (4 trials)

Drugs in Phase 1 Trials (2)

pxs-5382a (1 trial)

tpi 1100 (1 trial)

Drugs in Other Trials (1)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 3)

Bronchial Hyperreactivity (Phase 3)

Bronchiectasis (Phase 3)

Bronchitis (Phase 2)

Cystic Fibrosis (Phase 3)

Fibrosis (Phase 3)

Lung Diseases (Phase 2)

Lung Diseases, Obstructive (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 30
  • # of Trial APIs: 13